As of June 02, 2025, Novo Nordisk A/S (NOVO-B.CO) has a market cap of $321.63 billion USD. According to our data, Novo Nordisk A/S is ranked No.28 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jun 02, 2025 | $321.63 B |
2.06%
|
Dec 30, 2024 | $315.14 B |
-9.59%
|
Dec 29, 2023 | $348.58 B |
50.74%
|
Dec 30, 2022 | $231.25 B |
29.53%
|
Dec 30, 2021 | $178.53 B |
75.62%
|
Dec 30, 2020 | $101.65 B |
12.77%
|
Dec 30, 2019 | $90.14 B |
32.92%
|
Dec 28, 2018 | $67.81 B |
-8.60%
|
Dec 29, 2017 | $74.19 B |
35.35%
|
Dec 30, 2016 | $54.81 B |
-34.55%
|
Dec 30, 2015 | $83.74 B |
55.91%
|
Dec 30, 2014 | $53.71 B |
33.38%
|
Dec 30, 2013 | $40.27 B |
10.55%
|
Dec 28, 2012 | $36.43 B |
41.30%
|
Dec 30, 2011 | $25.78 B |
6.57%
|
Dec 30, 2010 | $24.19 B |
93.29%
|
Dec 30, 2009 | $12.52 B |
24.92%
|
Dec 30, 2008 | $10.02 B |
-17.97%
|
Dec 28, 2007 | $12.22 B |
44.53%
|
Dec 29, 2006 | $8.45 B |
34.90%
|
Dec 30, 2005 | $6.27 B |
-39.81%
|
Dec 31, 2004 | $10.41 B |
26.30%
|
Dec 31, 2003 | $8.24 B |
19.45%
|
Dec 31, 2002 | $6.90 B |
-39.51%
|
Dec 31, 2001 | $11.41 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Eli Lilly
LLY
|
$664.56 B |
-0.020 M
|
![]() USA
|
![]() Sanofi
SNY
|
$125.43 B |
5.543 B
|
![]() France
|
![]() AstraZeneca
AZN
|
$222.70 B |
-0.000 M
|
![]() UK
|
![]() Bristol-Myers Squibb
BMY
|
$99.18 B |
-0.004 M
|
![]() USA
|
![]() Merck
MRK
|
$190.56 B |
-0.025 B
|
![]() USA
|
![]() Pfizer
PFE
|
$133.09 B |
-0.057 B
|
![]() USA
|
![]() GlaxoSmithKline
GSK
|
$84.14 B |
0.003 M
|
![]() UK
|
![]() Johnson & Johnson
JNJ
|
$373.40 B |
-0.005 M
|
![]() USA
|
![]() AbbVie
ABBV
|
$329.43 B |
0.012 M
|
![]() USA
|
![]() Amgen
AMGN
|
$154.43 B |
0.000 M
|
![]() USA
|
![]() Novo Nordisk
NVO
|
$312.36 B |
67.643 B
|
![]() Denmark
|
![]() Teva Pharmaceutical Industries
TEVA
|
$20.79 B |
1.128 B
|
![]() Israel
|
Market Cap | = | NOVO-B.CO Stock Price | * | NOVO-B.CO Shares Outstanding |
= | $72.38 | * | 3.37 B | |
= | $321.63 B |